array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(29) "Regeneron Pharmaceuticals Inc"
["slug"]=>
string(38) "c469a-us-regeneron-pharmaceuticals-inc"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77"
["description"]=>
string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in.
Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media.
An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. "
["address_street"]=>
string(25) "777 Old Saw Mill River Rd"
["address_place"]=>
string(9) "Tarrytown"
["address_region"]=>
string(8) "New York"
["founding_date"]=>
string(10) "1988-02-08"
["website_domain"]=>
string(13) "regeneron.com"
["website_url"]=>
string(25) "https://www.regeneron.com"
["industry_codes"]=>
array(1) {
[0]=>
string(27) "Pharmaceutical Preparations"
}
["employee_count"]=>
int(10368)
["article_count"]=>
int(2748)
}
["articles"]=>
array(9) {
[0]=>
array(7) {
["title_en"]=>
string(74) "Harnessing Community Insights to Shape the Future of Hemophilia B Research"
["snippet_en"]=>
string(106) "Discover how Regeneron leverages community insights and collaboration to advance research in Hemophilia B."
["url"]=>
string(101) "https://hemaware.org/community-pulse/harnessing-community-insights-shape-future-hemophilia-b-research"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/ae6b18e1-a339-4c00-8dc3-0810666f5333"
["source"]=>
string(12) "hemaware.org"
["publication_date"]=>
string(10) "2024-10-04"
["categories"]=>
array(2) {
[0]=>
string(17) "Academic Research"
[1]=>
string(13) "Collaboration"
}
}
[1]=>
array(7) {
["title_en"]=>
string(90) "Zuellig Pharma joins hands with Regeneron to introduce Libtayo® to Taiwan and South Korea"
["snippet_en"]=>
string(558) "Taipei, Taiwan – Media OutReach Newswire – August 28, 2024 – Zuellig Pharma, Asia’s leading pharmaceutical and healthcare services provider, today announced that it has entered into a strategic partnership with Regeneron Pharmaceuticals, Inc., a global biotechnology leader. )'s wholly-owned subsidiary Regeneron Ireland DAC has signed an exclusive distribution agreement to introduce and promote Libtayo® (cemiplimab), a fully human monoclonal antibody targeting the T cell immune checkpoint receptor PD-1, in the Taiwan and South Korean markets. ."
["url"]=>
string(220) "https://www.macaubusiness.com/%E8%A3%95%E5%88%A9%E9%86%AB%E8%97%A5-zuellig-pharma-%E6%94%9C%E6%89%8B%E9%9B%B7%E5%82%91%E7%B4%8D%E6%A6%AE-regeneron-%E5%B0%87-libtayo-%E5%B0%8E%E5%85%A5%E5%8F%B0%E7%81%A3%E5%8F%8A%E5%8D%97/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/67a1e965-9cf0-4dae-8942-8ba9769e6451"
["source"]=>
string(17) "macaubusiness.com"
["publication_date"]=>
string(10) "2024-08-28"
["categories"]=>
array(2) {
[0]=>
string(15) "Deals & Tenders"
[1]=>
string(13) "Collaboration"
}
}
[2]=>
array(7) {
["title_en"]=>
string(24) "Better results for Bayer"
["snippet_en"]=>
string(161) "Bayer's sales improved, which is related to the growing demand for new oncology and urology drugs. Interestingly, cooperation with Regeneron was also successful."
["url"]=>
string(52) "https://isbiznes.pl/2024/08/07/lepsze-wyniki-bayera/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/17105381-d476-4016-ab13-bf0050603157"
["source"]=>
string(11) "isbiznes.pl"
["publication_date"]=>
string(10) "2024-08-07"
["categories"]=>
array(1) {
[0]=>
string(13) "Collaboration"
}
}
[3]=>
array(7) {
["title_en"]=>
string(239) "FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials"
["snippet_en"]=>
string(154) "FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO® in..."
["url"]=>
string(252) "https://www.globenewswire.com/news-release/2024/06/03/2892583/0/en/FibroGen-Announces-Clinical-Trial-Supply-Agreement-with-Regeneron-Pharmaceuticals-to-Evaluate-FibroGen-s-Immuno-Oncology-Assets-FG-3165-anti-Galectin-9-and-FG-3175-anti-CCR8-in-Com.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/a0565d33-55df-4f3f-a3a9-6946255bdb57"
["source"]=>
string(17) "globenewswire.com"
["publication_date"]=>
string(10) "2024-06-03"
["categories"]=>
array(2) {
[0]=>
string(15) "Deals & Tenders"
[1]=>
string(13) "Collaboration"
}
}
[4]=>
array(7) {
["title_en"]=>
string(53) "Competitors Need To Collaborate On Digital Biomarkers"
["snippet_en"]=>
string(146) "Regeneron’s second annual Digital Biomarkers Summit is a good example of how competing pharma companies can work together in a noncompetitive..."
["url"]=>
string(93) "https://www.clinicalleader.com/doc/competitors-need-to-collaborate-on-digital-biomarkers-0001"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/b98dd4fd-1810-4643-861c-15c9edd77115"
["source"]=>
string(18) "clinicalleader.com"
["publication_date"]=>
string(10) "2024-05-15"
["categories"]=>
array(1) {
[0]=>
string(13) "Collaboration"
}
}
[5]=>
array(7) {
["title_en"]=>
string(62) "Kukje Pharma to sell Celltion’s Eylea biosimilar exclusively"
["snippet_en"]=>
string(300) "Kukje Pharma said Tuesday that it has signed a strategic marketing partnership contract with Celltrion for the domestic sales of Celltrion's CT-P42 (aflibercept), an Eylea biosimilar, for treating ophthalmic retinal diseases.Under the agreement, Celltrion will exclusively provide Kukje Pharma with d"
["url"]=>
string(61) "https://www.koreabiomed.com/news/articleView.html?idxno=23727"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/ac3bc19e-c756-4d94-8464-57e09ecab462"
["source"]=>
string(15) "koreabiomed.com"
["publication_date"]=>
string(10) "2024-04-02"
["categories"]=>
array(1) {
[0]=>
string(13) "Collaboration"
}
}
[6]=>
array(7) {
["title_en"]=>
string(116) "Adium announces an exclusive distribution agreement with Regeneron for the commercialization of Cemiplimab in Brazil"
["snippet_en"]=>
string(148) "Pharmaceutical company Adium announces exclusive distribution agreement with Regeneron Ireland DAC, a wholly owned subsidiary of Regeneron, for Libt"
["url"]=>
string(136) "https://saludnews.net/adium-anuncia-un-acuerdo-de-distribucion-exclusiva-con-regeneron-para-la-comercializacion-de-cemiplimab-en-brasil/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/f9806725-d463-475f-baf3-e64255bac539"
["source"]=>
string(13) "saludnews.net"
["publication_date"]=>
string(10) "2024-03-30"
["categories"]=>
array(2) {
[0]=>
string(15) "Deals & Tenders"
[1]=>
string(13) "Collaboration"
}
}
[7]=>
array(7) {
["title_en"]=>
string(112) "2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron | TSVT Stock News"
["snippet_en"]=>
string(229) "2seventy bio, Inc. (Nasdaq: TSVT) has completed an asset purchase agreement with Regeneron Pharmaceuticals, Inc., focusing exclusively on the development and commercialization of Abecma, a CAR T cell therapy for multiple myeloma."
["url"]=>
string(115) "https://www.stocktitan.net/news/TSVT/2seventy-bio-announces-completion-of-oncology-and-autoimmune-65ex5m9fekls.html"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/dd4bdefa-472d-41a7-9009-ab29959775ab"
["source"]=>
string(14) "stocktitan.net"
["publication_date"]=>
string(10) "2024-03-20"
["categories"]=>
array(2) {
[0]=>
string(15) "Deals & Tenders"
[1]=>
string(13) "Collaboration"
}
}
[8]=>
array(7) {
["title_en"]=>
string(125) "Empowering Future Scientists: Hudson County's Annual STEM Showcase Celebrates Creativity and Technical Skills - News Chemical"
["snippet_en"]=>
string(155) "The annual Hudson County STEM Showcase, hosted by Jersey City Medical Center in partnership with Liberty Science Center, took place on March 11. This event"
["url"]=>
string(133) "https://newschemical.com/empowering-future-scientists-hudson-countys-annual-stem-showcase-celebrates-creativity-and-technical-skills/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/7207bc88-5215-4999-b7dc-f6b641397771"
["source"]=>
string(16) "newschemical.com"
["publication_date"]=>
string(10) "2024-03-16"
["categories"]=>
array(2) {
[0]=>
string(5) "Event"
[1]=>
string(13) "Collaboration"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(263)
}
[1]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(201)
}
[2]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(196)
}
[3]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(129)
}
[4]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(116)
}
[5]=>
array(2) {
["name"]=>
string(5) "Award"
["count"]=>
int(116)
}
[6]=>
array(2) {
["name"]=>
string(5) "Event"
["count"]=>
int(93)
}
[7]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(79)
}
[8]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(67)
}
[9]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(66)
}
[10]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(61)
}
[11]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(59)
}
[12]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(57)
}
[13]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(56)
}
[14]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(53)
}
[15]=>
array(2) {
["name"]=>
string(11) "Competition"
["count"]=>
int(43)
}
[16]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(40)
}
[17]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(38)
}
[18]=>
array(2) {
["name"]=>
string(14) "Issuing Shares"
["count"]=>
int(37)
}
[19]=>
array(2) {
["name"]=>
string(8) "Verdicts"
["count"]=>
int(37)
}
[20]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(37)
}
[21]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(35)
}
[22]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(33)
}
[23]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(32)
}
[24]=>
array(2) {
["name"]=>
string(13) "Data Security"
["count"]=>
int(31)
}
[25]=>
array(2) {
["name"]=>
string(27) "Business Model & Innovation"
["count"]=>
int(28)
}
[26]=>
array(2) {
["name"]=>
string(14) "Product Review"
["count"]=>
int(28)
}
[27]=>
array(2) {
["name"]=>
string(24) "Access and affordability"
["count"]=>
int(25)
}
[28]=>
array(2) {
["name"]=>
string(11) "Sponsorship"
["count"]=>
int(21)
}
[29]=>
array(2) {
["name"]=>
string(21) "Intellectual Property"
["count"]=>
int(20)
}
}
}
c469a-us-regeneron-pharmaceuticals-inc
Website
https://www.regeneron.com
Category
Pharmaceutical Preparations
Description
At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in.
Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media.
An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media.
Articles
2024-10-04 (hemaware.org)
Discover how Regeneron leverages community insights and collaboration to advance research in Hemophilia B.
Read more
2024-08-28 (macaubusiness.com)
Taipei, Taiwan – Media OutReach Newswire – August 28, 2024 – Zuellig Pharma, Asia’s leading pharmaceutical and healthcare services provider, today announced that it has entered into a strategic partnership with Regeneron Pharmaceuticals, Inc., a global biotechnology leader. )'s wholly-owned subsidiary Regeneron Ireland DAC has signed an exclusive distribution agreement to introduce and promote Libtayo® (cemiplimab), a fully human monoclonal antibody targeting the T cell immune checkpoint receptor PD-1, in the Taiwan and South Korean markets. .
Read more
2024-08-07 (isbiznes.pl)
Bayer's sales improved, which is related to the growing demand for new oncology and urology drugs. Interestingly, cooperation with Regeneron was also successful.
Read more
2024-06-03 (globenewswire.com)
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO® in...
Read more
2024-05-15 (clinicalleader.com)
Regeneron’s second annual Digital Biomarkers Summit is a good example of how competing pharma companies can work together in a noncompetitive...
Read more
2024-04-02 (koreabiomed.com)
Kukje Pharma said Tuesday that it has signed a strategic marketing partnership contract with Celltrion for the domestic sales of Celltrion's CT-P42 (aflibercept), an Eylea biosimilar, for treating ophthalmic retinal diseases.Under the agreement, Celltrion will exclusively provide Kukje Pharma with d
Read more
2024-03-30 (saludnews.net)
Pharmaceutical company Adium announces exclusive distribution agreement with Regeneron Ireland DAC, a wholly owned subsidiary of Regeneron, for Libt
Read more
2024-03-20 (stocktitan.net)
2seventy bio, Inc. (Nasdaq: TSVT) has completed an asset purchase agreement with Regeneron Pharmaceuticals, Inc., focusing exclusively on the development and commercialization of Abecma, a CAR T cell therapy for multiple myeloma.
Read more
2024-03-16 (newschemical.com)
The annual Hudson County STEM Showcase, hosted by Jersey City Medical Center in partnership with Liberty Science Center, took place on March 11. This event
Read more